Recent progress in systemic treatment for lung cancer
| Autor: | Dan L. Longo, Jeffrey W. Clark |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Antineoplastic Agents Targeted therapy Proto-Oncogene Proteins p21(ras) 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Carcinoma Non-Small-Cell Lung Proto-Oncogene Proteins Internal medicine ROS1 medicine Humans Anaplastic Lymphoma Kinase Molecular Targeted Therapy 030212 general & internal medicine Epidermal growth factor receptor Lung cancer Protein Kinase Inhibitors Chemotherapy biology business.industry Immunosuppression Combination chemotherapy Immunotherapy Protein-Tyrosine Kinases medicine.disease Small Cell Lung Carcinoma ErbB Receptors Drug Resistance Neoplasm 030220 oncology & carcinogenesis Mutation biology.protein business |
| Zdroj: | Current Opinion in Pulmonary Medicine. 24:355-366 |
| ISSN: | 1070-5287 |
| Popis: | Purpose of review We intend to highlight progress made in 2017 to lung cancer molecular nosology and application of new knowledge to treatment. Recent findings Studies have shown that agents targeting specific molecular defects in lung cancers such as epidermal growth factor receptor(egfr) mutations, alk or ros1 gene rearrangements, are more effective than conventional combination chemotherapy as primary treatment for various lung cancer subgroups. Identification of mechanisms of drug resistance has guided development of improved agents and effective salvage regimens. Progress in reversing tumor-induced immunosuppression has led to further improvements in response rates (RR) including some patients with prolonged durable remissions. Summary State-of-the-art management of patients with lung cancer requires information derived from tumor molecular analysis, obtained either directly from the tumor or from tumor-derived circulating DNA. Empiric combination chemotherapy is no longer uniformly the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of molecular features of an individual patient's tumor. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|